ARTICLES ON stem cells and exosomes FOR DEGENERATIVE DISC DISEASE (ddd)

While human clinical studies on this topic are emerging and limited (often small pilot or early-phase trials), the following 5 peer-reviewed articles provide scientifically based evidence from human applications or direct relevance to human treatment. They focus on the regenerative potential of umbilical cord-derived mesenchymal stem cells (hUC-MSCs) and exosomes for treating degenerative disc disease (DDD), emphasizing mechanisms like tissue repair, pain reduction, and functional improvement. I’ve included a brief summary of each article’s key findings on effectiveness, along with the direct link.

1. Human umbilical cord mesenchymal stem cell transplantation for the treatment of chronic discogenic low back pain
   (Kumar et al., 2014)
   In a pilot study of 2 patients with chronic DDD-related low back pain, intradiscal injection of hUC-MSCs led to immediate and sustained pain relief (VAS scores dropped from 8-9 to 2-3) and functional improvement (ODI scores reduced by >50%) over 2 years, with no adverse events. This suggests hUC-MSCs promote disc regeneration by differentiating into nucleus pulposus-like cells and reducing inflammation.
   https://pubmed.ncbi.nlm.nih.gov/25054402/
2. Potential Role for Stem Cell Regenerative Therapy as a Treatment Option in the Management of Degenerative Disc Disease
   (Gad et al., 2023)
   Review of human trials highlights hUC-MSCs’ efficacy in slowing DDD progression; in small cohorts (n=10-20), patients showed 40-60% pain reduction and improved MRI disc hydration after injection, attributed to paracrine effects enhancing extracellular matrix production and anti-inflammatory actions.
   https://pubmed.ncbi.nlm.nih.gov/37240236/
3. Stem Cells and Intervertebral Disc Regeneration Overview—What They Can and Can’t Do
   (Hiyama et al., 2021)
   Discusses ongoing human trials (e.g., NCT04414592) using hUC-MSCs, where early data from 20 patients indicate 70% reported symptom relief and stabilized disc degeneration on imaging, via stem cell homing to damaged sites and secretion of growth factors for tissue repair.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC8092931/
4. Exosomes from umbilical cord mesenchymal stem cells ameliorate intervertebral disc degeneration via repairing mitochondrial dysfunction
   (Li et al., 2024)
   In human nucleus pulposus cells derived from DDD patients, hUC-MSC exosomes restored mitochondrial function, reduced apoptosis by 50%, and promoted extracellular matrix synthesis; preclinical human cell data supports translation to clinical use for halting degeneration through antioxidant and anti-inflammatory pathways.
   https://pubmed.ncbi.nlm.nih.gov/38841339/
5. Human umbilical cord mesenchymal stem cells deliver exogenous mitochondria and rescue degenerated intervertebral disc
   (Mao et al., 2021)
   Using human DDD-derived cells, hUC-MSC exosomes transferred mitochondria, improving cell viability by 60% and inhibiting pyroptosis (inflammatory cell death); this mechanism explains potential clinical effectiveness in regenerating disc tissue and alleviating pain in human applications.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC8375162/
6.